In a female patient with attention-deficit/hyperactivity disorder who is taking Vyvanse (lisdexamfetamine) 50 mg and showing increased aggression, what alternative medications can be used?

Switch to Non-Stimulant ADHD Medication

If your patient is experiencing increased aggression on Vyvanse 50mg, you should switch to atomoxetine as the first-line non-stimulant alternative, or consider alpha-2 agonists (guanfacine extended-release or clonidine extended-release) as these medications are specifically indicated for patients with disruptive behavior disorders and aggression. 1

Why This Switch is Necessary

The FDA label for Vyvanse explicitly warns about psychiatric adverse reactions, including new psychotic or manic symptoms, and recommends considering discontinuation when these occur 2. Aggression represents a significant behavioral adverse effect that warrants medication change rather than dose adjustment.

Recommended Alternative Medications

First Choice: Atomoxetine

• Dosing: Start 40mg daily, increase after minimum 3 days to target of 80mg daily (can go up to 100mg if needed)
• Advantages for your patient:
  • Non-controlled substance (no abuse potential)
  • Around-the-clock symptom coverage
  • Specifically beneficial for comorbid disruptive behavior disorders 1
  • Effect size of 0.7 (compared to 1.0 for stimulants) 3
• Timeline: Expect 6-12 weeks for full therapeutic effect 1
• Monitoring: Watch for suicidality (black box warning), pulse, blood pressure

Second Choice: Guanfacine Extended-Release

• Dosing: Start 1mg at bedtime, titrate weekly by 1mg to target 2-4mg daily
• Advantages for your patient:
  • First-line option specifically for disruptive behavior disorders and aggression 1
  • May reduce oppositional symptoms
  • Around-the-clock coverage
  • Non-controlled substance
• Key consideration: Administer at bedtime due to sedation/somnolence 1
• Timeline: 2-4 weeks for effect 1

Third Choice: Clonidine Extended-Release

• Dosing: Start 0.1mg at bedtime, titrate weekly to 0.2-0.4mg daily
• Similar profile to guanfacine but requires twice-daily dosing (less convenient) 1
• Also indicated for disruptive behavior disorders 1

Critical Clinical Considerations

Do NOT Simply Switch to Another Stimulant

While methylphenidate is an alternative stimulant, approximately 40% of patients respond to both methylphenidate and amphetamines, meaning switching stimulants may not resolve the aggression 3. The aggression suggests this patient may be in the subset who experiences behavioral adverse effects from stimulant class medications generally.

Evidence on Aggression in ADHD

Research specifically examining aggression in ADHD patients found that 63% of children with ADHD and aggressive behavior achieved remission with optimized stimulant monotherapy plus behavioral therapy 4. However, your patient has failed this approach, placing her in the 37% who need alternative treatment.

What About Adjunctive Therapy?

The evidence shows risperidone or divalproex can be added to stimulants for persistent aggression 4, but this approach increases adverse effect burden (risperidone causes significant weight gain). Switching to a non-stimulant that treats both ADHD and aggression is preferable to polypharmacy.

Implementation Algorithm

1. Discontinue Vyvanse (can stop abruptly as it's not associated with withdrawal syndrome requiring taper)
2. Start atomoxetine 40mg daily (morning or evening dosing acceptable)
3. Increase to 80mg after 3-7 days if tolerated
4. Reassess at 4 weeks for tolerability, at 8-12 weeks for efficacy
5. If inadequate response: Consider switching to guanfacine ER or adding behavioral therapy intensification

Monitoring Parameters

• Baseline: Blood pressure, pulse, height, weight
• Ongoing: Monitor aggression weekly for first month, then monthly
• Atomoxetine-specific: Screen for suicidal ideation at each visit (black box warning)
• Long-term: Growth parameters every 3 months in pediatric patients

Common Pitfalls to Avoid

• Don't increase Vyvanse dose thinking higher doses will help—stimulant-induced aggression typically worsens with dose escalation
• Don't switch to immediate-release dexamphetamine—this is the active metabolite of lisdexamfetamine and will cause the same problem 2
• Don't expect immediate results with atomoxetine—counsel patient/family about 6-12 week timeline to prevent premature discontinuation 1

3, 1, 2, 4